Evidence map›Paper›PMID 24482631›Full record

ArticleMetabolomics : Official journal of the Metabolomic Society2014

Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells.

Mary Jo Cantoria, László G Boros, Emmanuelle J Meuillet

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolomics : Official journal of the Metabolomic Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects.Journal of experimental & clinical cancer research : CR · 2019
    Review
  4. p13CMFA: Parsimonious 13C metabolic flux analysis.PLoS computational biology · 2019
    Article
  5. Potential application of cell reprogramming techniques for cancer research.Cellular and molecular life sciences : CMLS · 2019
    Review
  6. Review
  7. Review
  8. Metabolomics in pancreatic cancer biomarkers research.Medical oncology (Northwood, London, England) · 2016
    Review
  9. Diabetes mellitus and metformin in hepatocellular carcinoma.World journal of gastroenterology · 2016
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Mary Jo CantoriaDepartment of Nutritional Sciences, The University of Arizona, 1177 East 4th Street, Shantz Building #309, P.O. Box 210038, Tucson, AZ 85721-0038 USA.
László G BorosSiDMAP, LLC, 2990 South Sepulveda Blvd. #300B, Los Angeles, CA 90064 USA.
Emmanuelle J MeuilletThe University of Arizona Cancer Center, 1515 N. Campbell Ave Levy Building, Tucson, AZ 85724 USA.
University of Arizona · USUniversity of Arizona Cancer Center

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCLA Center for Excellence in Pancreatic DiseasesP01AT003960 · NCCIH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HINES, OSCAR JOE · 2007 to 2011
$5.6M
NCATS NIH HHS UL1 TR000124NCCIH NIH HHS P01 AT003960
6 · The paper itself

Abstract

Metformin, a generic glucose lowering drug, inhibits cancer growth expressly in models that employ high fat/cholesterol intake and/or low glucose availability. Here we use a targeted tracer fate association study (TTFAS) to investigate how cholesterol and metformin administration regulates glucose-derived intermediary metabolism and macromolecule synthesis in pancreatic cancer cells. Wild type K-

Indexed as

13C glucose-derived acetyl-CoACholesterolContextual drug effectSystem-wide association studyTargeted tracer fate association studyTTFAS

Identifiers

PMID24482631
PMCPMC3890070
OpenAlexW2122153412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.